Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
Martine Piccart(Institut Jules Bordet), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Mario Campone(Institut de Cancérologie de l'Ouest), Kathleen I. Pritchard(University of Toronto), Fabienne Lebrun(Institut Jules Bordet), Yoshiaki Ito(Japanese Foundation For Cancer Research), Shinzaburo Noguchi(Osaka University), Alejandra Perez, Hope S. Rugo(University of California, San Francisco), Ines Deleu(Vlaamse Vereniging voor Obstetrie en Gynaecolo), Howard A. Burris(Sarah Cannon), Louise Provencher(Hôpital du Saint-Sacrement), Patrick Neven(KU Leuven), Michael Gnant(Comprehensive Cancer Center Vienna), Mikhail Shtivelband(Ironwood Pharmaceuticals (United States)), Cheng-Han Wu(Novartis (Switzerland)), Jiaxin Fan(Novartis (Switzerland)), Wentao Feng(Novartis (Switzerland)), T Taran(Novartis (Switzerland)), José Baselga(Memorial Sloan Kettering Cancer Center)
Cited by 567Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis